Trial
NCT04723186
MT1002 Phase II Study in ACS Patients With PCI
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Collaborators
—
Condition
Acute Coronary Syndrome
Intervention
MT1002 for Injection
Why stopped
The study was decided to be terminated due to commercial considerations,（not the safety issues of the product）.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-27